Simon Gamblin is a partner in the firm's corporate and commercial team. He has extensive international and domestic corporate finance expertise, including substantial experience advising on complex public and private mergers and acquisitions, joint ventures (typically with a cross-border element), restructurings, financings (including early-stage), private equity and general corporate/commercial transactions, as well as corporate governance issues.
His practice spans many sectors including education, life sciences and healthcare, technology, media and renewables.
相关经验
Advising TransactPay, a licensed E-Money Institution (EMI) to issue e-money and undertake payment services in the UK and European Economic Area, in respect of its acquisition by Marqeta Inc, the global card issuing platform that enables embedded finance solutions for the world’s innovators.
Advising founder, Mr. Dimitris Spyridis, on the part sale of his minority stake in Hellenic Healthcare Group (“HHG”), the largest private healthcare provider in Greece and Cyprus, to PureHealth Holding PJSC (“PureHealth”), the largest healthcare group in the Middle East, in a transaction that values HHG at EUR 2.3 billion.
Advising the majority shareholders on the sale of Chronos Therapeutics Limited ("Chronos") to Evgen Pharma plc, a clinical stage drug development company ("Evgen").
Advising Accentus Medical in respect of sale to STS Group.
Advising Urban & Civic, one of the UK’s leading Master Developers of large-scale strategic sites, on its acquisition of Todds Nursery, a specialist supplier of mature trees, shrubs and hedging plants.
Advising Chatworth Schools in respect of acquisition of UK school portfolio and establishment in the Kingdom of Saudi Arabia.
